NZ796403B2 - Therapeutic herbal compositions for improving joint health - Google Patents
Therapeutic herbal compositions for improving joint health Download PDFInfo
- Publication number
- NZ796403B2 NZ796403B2 NZ796403A NZ79640321A NZ796403B2 NZ 796403 B2 NZ796403 B2 NZ 796403B2 NZ 796403 A NZ796403 A NZ 796403A NZ 79640321 A NZ79640321 A NZ 79640321A NZ 796403 B2 NZ796403 B2 NZ 796403B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- extract
- concentrated
- pharmaceutically acceptable
- solvate
- use according
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 56
- 230000037231 joint health Effects 0.000 title claims abstract 10
- 230000001225 therapeutic effect Effects 0.000 title 1
- 239000000284 extract Substances 0.000 claims abstract 107
- 241000871264 Cardiospermum halicacabum Species 0.000 claims abstract 23
- 244000248021 Vitex negundo Species 0.000 claims abstract 23
- 235000010363 Vitex negundo Nutrition 0.000 claims abstract 23
- 235000017166 Bambusa arundinacea Nutrition 0.000 claims abstract 19
- 150000003839 salts Chemical class 0.000 claims 30
- 239000012453 solvate Substances 0.000 claims 30
- 244000271437 Bambusa arundinacea Species 0.000 claims 18
- 240000007551 Boswellia serrata Species 0.000 claims 18
- 235000012035 Boswellia serrata Nutrition 0.000 claims 18
- 240000002319 Citrus sinensis Species 0.000 claims 18
- 235000005976 Citrus sinensis Nutrition 0.000 claims 18
- 239000008513 turmeric extract Substances 0.000 claims 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 8
- ZUKLFFYDSALIQW-MSUKCBDUSA-N Iridoid glycoside Chemical compound [H][C@]12CC[C@H](C(O)=O)[C@@]1([H])[C@H](OC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)OC=C2 ZUKLFFYDSALIQW-MSUKCBDUSA-N 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 8
- 229930182489 iridoid glycoside Natural products 0.000 claims 8
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 6
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 229960002442 glucosamine Drugs 0.000 claims 6
- 239000000377 silicon dioxide Substances 0.000 claims 6
- 239000002253 acid Substances 0.000 claims 4
- 239000003963 antioxidant agent Substances 0.000 claims 4
- 230000003078 antioxidant effect Effects 0.000 claims 4
- 235000006708 antioxidants Nutrition 0.000 claims 4
- 150000002212 flavone derivatives Chemical class 0.000 claims 4
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Chemical class O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 claims 4
- 229930182470 glycoside Natural products 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims 4
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 claims 4
- 229930182490 saponin Natural products 0.000 claims 4
- -1 saponin glycoside Chemical class 0.000 claims 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 4
- 244000163122 Curcuma domestica Species 0.000 claims 2
- 235000003373 curcuma longa Nutrition 0.000 claims 2
- 238000000605 extraction Methods 0.000 claims 2
- 210000003127 knee Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 241001227486 Bambusa bambos Species 0.000 abstract 1
- 239000012676 herbal extract Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
Abstract
Compositions including herbal extracts, such as a Vitex negundo extract, a Cardiospermum halicacabum extract, and a Bambusa arundinacea extract, and methods using such compositions are disclosed. For example, compositions and methods may be used to improve joint health.
Claims (34)
1. A use of an effective amount of an herbal composition in the manufacture of a medicament for improving or maintaining joint health or increasing joint space in a subject, wherein the herbal composition comprises: from about 29% to about 35% of a concentrated Vitex negundo extract, by weight relative to the total weight of the herbal composition, concentrated in at least one iridoid glycoside or a pharmaceutically acceptable salt or solvate thereof; from about 34% to about 40% of a concentrated Cardiospermum halicacabum extract, by weight relative to the total weight of the herbal composition, concentrated in at least one hydroxy flavone derivative or a pharmaceutically acceptable salt or solvate thereof; from about 4% to about 8% of a concentrated Bambusa arundinacea extract, by weight relative to the total weight of the herbal composition, concentrated in silica; from about 2% to about 6% of a concentrated Citrus sinensis extract, by weight relative to the total weight of the herbal composition, concentrated in at least one bioflavonoid or a pharmaceutically acceptable salt or solvate thereof; from about 2% to about 6% of a concentrated Boswellia serrata extract, by weight relative to the total weight of the herbal composition, concentrated in at least one pentacyclic triterpenic acid or a pharmaceutically acceptable salt or solvate thereof; and from about 12% to about 18% of a concentrated Curcuma longa extract, by weight relative to the total weight of the herbal composition, concentrated in at least one water soluble saponin glycoside or a pharmaceutically acceptable salt or solvate thereof; wherein the combination of the amount of the composition comprising the concentrated Vitex negundo extract, the concentrated Cardiospermum halicacabum extract, the concentrated Bambusa arundinacea extract, the concentrated Citrus sinensis extract, the concentrated Boswellia serrata extract, and the concentrated Curcuma longa extract is effective to improve or maintain joint health or increase joint space in the subject.
2. The use according to claim 1, wherein the ratio of the concentrated Vitex negundo extract to the concentrated Cardiospermum halicacabum extract is from about 1:1 to about 1:2.5.
3. The use according to claim 1, wherein the composition comprises about 32.5% of the Vitex negundo extract, about 37.5% of the Cardiospermum halicacabum extract, about 5% of the Bambusa arundinacea extract, about 5% of the Citrus sinensis extract, about 5% of the Boswellia serrata extract, and about 15% of the Curcuma longa extract, by weight relative to the total weight of the composition.
4. The use according to claim 1, wherein each extract is standardized to a powder comprised of particles of substantially uniform size before being mixed with other extracts.
5. The use according to claim 2, wherein the Vitex negundo extract is an extract from Vitex negundo aerial parts, the Cardiospermum halicacabum extract is an extract from Cardiospermum halicacabum aerial parts, the Bambusa arundinacea extract is an extract from Bambusa arundinacea shoots, the Citrus sinensis extract is an extract of Citrus sinensis peels, the Boswellia serrata extract is an extract of Boswellia serrata gum, and the Curcuma longa extract is an extract of Curcuma longa rhizomes.
6. The use according to claim 3, wherein the amount of the composition comprising the Vitex negundo extract, the Cardiospermum halicacabum extract, the Bambusa arundinacea extract, the Citrus sinensis extract, the Boswellia serrata extract, and the Curcuma longa extract is effective to improve or maintain joint health or reduce, alleviate, and/or slow the progression of at least one symptom in the subject as shown by improvement in the subject’s joint health as measured by changes in baseline versus end point scores in: a 30 second chair stand test (30SCST); a Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score (WOMAC A Pain), (WOMAC B Stiffness), and/or (WOMAC C Physical function); range of motion in knee flexion; and/or radiographic minimum joint space width.
7. The use according to claim 6, wherein the composition is effective to increase joint space in a subject as measured by changes in baseline versus endpoint scores in radiographic minimum joint space.
8. The use according to claim 4, wherein the Vitex negundo extract, the Cardiospermum halicacabum extract, the Citrus sinensis extract, the Boswellia serrata gum extract, and the Curcuma longa extract are from one or more extractions with aqueous alcohol.
9. The use according to claim 8, wherein the alcohol comprises methanol, ethanol, or combinations thereof.
10. The use according to claim 5, wherein the composition further comprises at least one pharmaceutically acceptable excipient and/or antioxidant.
11. A use of an effective amount of an herbal composition in the manufacture of a medicament for improving or maintaining joint health or increasing joint space in a subject, wherein the herbal composition comprises: from about 8% to about 12% of a concentrated Vitex negundo extract, by weight relative to the total weight of the herbal composition, concentrated in at least one iridoid glycoside or a pharmaceutically acceptable salt or solvate thereof; from about 18% to about 22% of a concentrated Cardiospermum halicacabum extract, by weight relative to the total weight of the herbal composition, concentrated in at least one hydroxy flavone derivative or a pharmaceutically acceptable salt or solvate thereof; from about 4% to about 8% of a concentrated Bambusa arundinacea extract, by weight relative to the total weight of the herbal composition, concentrated in silica; from about 3% to about 6% of a concentrated Citrus sinensis extract, by weight relative to the total weight of the herbal composition, concentrated in at least one bioflavonoid or a pharmaceutically acceptable salt or solvate thereof; from about 4% to about 6% of a concentrated Boswellia serrata extract, by weight relative to the total weight of the herbal composition, concentrated in at least one pentacyclic triterpenic acid or a pharmaceutically acceptable salt or solvate thereof; from about 12% to about 18% of a concentrated Curcuma longa extract, by weight relative to the total weight of the herbal composition, concentrated in at least one water soluble saponin glycoside or a pharmaceutically acceptable salt or solvate thereof; and from about 37% to about 42% of Glucosamine or a pharmaceutically acceptable salt or solvate thereof; wherein the amount of the composition comprising the concentrated Vitex negundo extract, the concentrated Cardiospermum halicacabum extract, the concentrated Bambusa arundinacea extract, the concentrated Citrus sinensis extract, the concentrated Boswellia serrata extract, the concentrated Curcuma longa extract, and the Glucosamine is effective to improve or maintain joint health or increase joint space in the subject.
12. The use according to claim 11, wherein the ratio of the concentrated Vitex negundo extract to the concentrated Cardiospermum halicacabum extract is from about 1:1.5 to about 1:2.5.
13. The use according to claim 11, wherein the composition comprises about 10% of the Vitex negundo extract, about 20% of the Cardiospermum halicacabum extract, about 5% of the Bambusa arundinacea extract, about 4% of the Citrus sinensis extract, about 5% of the Boswellia serrata extract, about 15% of the Curcuma longa extract, and about 40% of the Glucosamine, by weight relative to the total weight of the composition.
14. The use according to claim 11, wherein each extract is standardized to a powder comprised of particles of substantially uniform size before being mixed with other extracts.
15. The use according to claim 12, wherein the Vitex negundo extract is an extract from Vitex negundo aerial parts, the Cardiospermum halicacabum extract is an extract from Cardiospermum halicacabum aerial parts, the Bambusa arundinacea extract is an extract from Bambusa arundinacea shoots, the Citrus sinensis extract is an extract of Citrus sinensis peels, the Boswellia serrata extract is an extract of Boswellia serrata gum, and the Curcuma longa extract is an extract of Curcuma longa rhizomes.
16. The use according to claim 13, wherein the amount of the composition comprising the Vitex negundo extract, the Cardiospermum halicacabum extract, the Bambusa arundinacea extract, the Citrus sinensis extract, the Boswellia serrata extract, the Curcuma longa extract, and the Glucosamine is effective to improve or maintain joint health or reduce, alleviate, and/or slow the progression of at least one symptom in the subject as shown by improvement in the subject’s joint health as measured by changes in baseline versus end point scores in: a 30 second chair stand test (30SCST); a Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score (WOMAC A Pain), (WOMAC B Stiffness), and/or (WOMAC C Physical function); range of motion in knee flexion; and/or radiographic minimum joint space width.
17. The use according to claim 11, wherein the Vitex negundo extract, the Cardiospermum halicacabum extract, the Citrus sinensis extract, the Boswellia serrata gum extract, and the Curcuma longa extract are from one or more extractions with aqueous alcohol.
18. The use according to claim 17, wherein the alcohol comprises methanol, ethanol, or combinations thereof.
19. The use according to claim 15, wherein the composition further comprises at least one pharmaceutically acceptable excipient and/or antioxidant.
20. The use according to claim 16, wherein the composition is effective to increase joint space in a subject as measured by changes in baseline versus endpoint scores in radiographic minimum joint space.
21. The use according to claim 1, wherein the at least one iridoid glycoside is a compound according to Formula (I): or a pharmaceutically acceptable salt of solvate thereof; and wherein the at least one flavone derivative is a compound according to Formula (II): or a pharmaceutically acceptable salt of solvate thereof.
22. The use according to claim 11, wherein the at least one iridoid glycoside is a compound according to Formula (I) or a pharmaceutically acceptable salt of solvate thereof; and wherein the at least one flavone derivative is a compound according to Formula (II) or a pharmaceutically acceptable salt of solvate thereof.
23. The use according to claim 1, wherein the medicament is adapted to orally administer to a human subject the herbal composition in the effective amount of about 0.1 g to about 4 g per day for at least about 30 days, or the medicament is adapted to topically administer to a human subject an herbal composition in an effective amount of about 0.1 g to about 10 g per day for at least about 30 days, wherein the herbal composition consists essentially of: from about 29% to about 35% of a concentrated Vitex negundo extract, by weight relative to the total weight of the herbal composition, concentrated in at least one iridoid glycoside or a pharmaceutically acceptable salt or solvate thereof; from about 34% to about 40% of a concentrated Cardiospermum halicacabum extract, by weight relative to the total weight of the herbal composition, concentrated in at least one hydroxy flavone derivative or a pharmaceutically acceptable salt or solvate thereof; from about 4% to about 8% of a concentrated Bambusa arundinacea extract, by weight relative to the total weight of the herbal composition, concentrated in silica; from about 2% to about 6% of a concentrated Citrus sinensis extract, by weight relative to the total weight of the herbal composition, concentrated in at least one bioflavonoid or a pharmaceutically acceptable salt or solvate thereof; from about 2% to about 6% of a concentrated Boswellia serrata extract, by weight relative to the total weight of the herbal composition, concentrated in at least one pentacyclic triterpenic acid or a pharmaceutically acceptable salt or solvate thereof; and from about 12% to about 18% of a concentrated Curcuma longa extract, by weight relative to the total weight of the herbal composition, concentrated in at least one water soluble saponin glycoside or a pharmaceutically acceptable salt or solvate thereof.
24. The use according to claim 23, wherein the composition further comprises at least one pharmaceutically acceptable excipient and/or antioxidant.
25. The use according to claim 24, wherein the ratio of the concentrated Vitex negundo extract to the concentrated Cardiospermum halicacabum extract is from about 1:1 to about 1:2.5.
26. The use according to claim 24, wherein the composition comprises about 32.5% of the Vitex negundo extract, about 37.5% of the Cardiospermum halicacabum extract, about 5% of the Bambusa arundinacea extract, about 5% of the Citrus sinensis extract, about 5% of the Boswellia serrata extract, and about 15% of the Curcuma longa extract, by weight relative to the total weight of the composition.
27. The use according to claim 26, wherein the Bambusa arundinacea extract comprises about 50% to about 75% by weight silica.
28. The use according to claim 23, wherein the at least one iridoid glycoside is a compound according to Formula (I) or a pharmaceutically acceptable salt of solvate thereof; and wherein the at least one flavone derivative is a compound according to Formula (II) or a pharmaceutically acceptable salt of solvate thereof.
29. The use according to claim 11, wherein the medicament is adapted to orally administer to a human subject an herbal composition in an effective amount of about 0.1 g to about 4 g per day for at least about 30 days, or the medicament is adapted to topically administer to a human subject an herbal composition in an effective amount of about 0.1 g to about 10 g per day for at least about 30 days, wherein the herbal composition consists essentially of: from about 8% to about 12% of a concentrated Vitex negundo extract, by weight relative to the total weight of the herbal composition, concentrated in at least one iridoid glycoside or a pharmaceutically acceptable salt or solvate thereof; from about 18% to about 22% of a concentrated Cardiospermum halicacabum extract, by weight relative to the total weight of the herbal composition, concentrated in at least one hydroxy flavone derivative or a pharmaceutically acceptable salt or solvate thereof; from about 4% to about 8% of a concentrated Bambusa arundinacea extract, by weight relative to the total weight of the herbal composition, concentrated in silica; from about 3% to about 6% of a concentrated Citrus sinensis extract, by weight relative to the total weight of the herbal composition, concentrated in at least one bioflavonoid or a pharmaceutically acceptable salt or solvate thereof; from about 4% to about 6% of a concentrated Boswellia serrata extract, by weight relative to the total weight of the herbal composition, concentrated in at least one pentacyclic triterpenic acid or a pharmaceutically acceptable salt or solvate thereof; from about 12% to about 18% of a concentrated Curcuma longa extract, by weight relative to the total weight of the herbal composition, concentrated in at least one water soluble saponin glycoside or a pharmaceutically acceptable salt or solvate thereof; and from about 37% to about 42% of Glucosamine or a pharmaceutically acceptable salt or solvate thereof.
30. The use according to claim 29, wherein the composition further comprises at least one pharmaceutically acceptable excipient and/or antioxidant.
31. The use according to claim 30, wherein the ratio of the concentrated Vitex negundo extract to the concentrated Cardiospermum halicacabum extract is from about 1:1 to about 1:2.5.
32. The use according to claim 30, wherein the composition comprises about 10% of the Vitex negundo extract, about 20% of the Cardiospermum halicacabum extract, about 5% of the Bambusa arundinacea extract, about 4% of the Citrus sinensis extract, about 5% of the Boswellia serrata extract, about 15% of the Curcuma longa extract, and about 40% of the Glucosamine, by weight relative to the total weight of the composition.
33. The use according to claim 32, wherein the Bambusa arundinacea extract comprises about 50% to about 75% by weight silica.
34. The use according to claim 29, wherein the at least one iridoid glycoside is a compound according to Formula (I) or a pharmaceutically acceptable salt of solvate thereof; and wherein the at least one flavone derivative is a compound according to Formula (II) or a pharmaceutically acceptable salt of solvate thereof.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16/946,721 US11364255B2 (en) | 2020-07-01 | 2020-07-01 | Therapeutic herbal compositions for improving joint health |
| PCT/US2021/070723 WO2022006572A1 (en) | 2020-07-01 | 2021-06-17 | Therapeutic herbal compositions for improving joint health |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ796403A NZ796403A (en) | 2023-11-24 |
| NZ796403B2 true NZ796403B2 (en) | 2024-02-27 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kaur et al. | Pharmacological actions of Opuntia ficus indica: A Review | |
| Gaire et al. | Phytochemistry, pharmacology and medicinal properties of Phyllanthus emblica Linn. | |
| Rashan et al. | Boswellia gum resin and essential oils: Potential health benefits− An evidence based review | |
| Mir et al. | Prunella vulgaris L: critical pharmacological, expository traditional uses and extensive phytochemistry: a review | |
| Verma et al. | Unmasking the many faces of Giloy (Tinospora cordifolia L.): a fresh look on its phytochemical and medicinal properties | |
| Murthy et al. | Bioactive compounds of bael (Aegle marmelos (L.) correa) | |
| Al-Snafi | Arabian medicinal plants with antiinflammatory effects-plant based review (part 1) | |
| Ren et al. | Traditional uses, phytochemistry, pharmacology and toxicology of rhizoma phragmitis: a narrative review | |
| Patel et al. | Therapeutic significance of Abutilon indicum: An overview | |
| Sovrlić et al. | Plants from the genus Daphne: A review of its traditional uses, phytochemistry, biological and pharmacological activity | |
| Javadi et al. | Anticancer plants in Islamic traditional medicine | |
| Patel et al. | Bamboo a supplement to human health: a comprehensive review on its ethnopharmacology, phytochemistry, and pharmacological activity | |
| Shokry et al. | Phytochemical contents, biological activities and therapeutic applications of hedera helix (ivy leaf) extracts: a review | |
| Shivaprasad et al. | Ethnopharmacological and phytomedical knowledge of Coleus forskohlii: an approach towards its safety and therapeutic value | |
| Giri et al. | Traditional Uses, Phytochemistry and Pharmacological Activities of Woodfordia fruticosa (L) Kurz: A Comprehensive Review. | |
| Bhagat | Indian gooseberry (Emblica officinalis): Pharmacognosy review | |
| Dubey et al. | Anthocephalus cadamba: A review | |
| Harish et al. | Indian Medicinal Plants with Multiple Pharmacological Efficacies: A Comprehensive Review. | |
| Adewale et al. | Historical, botanical and medicinal perspectives on ginger (Zingiber officinale) | |
| Pansare et al. | Ayurvedic and modern aspects of Sariva (Hemidesmus indicus R. Br): An overview | |
| Desai et al. | A Review on Terminalia arjuna (Roxb.) Wight & Arn.: the wonder medicinal plant with prodigious potential in therapeutics | |
| Diwan et al. | Tradition and medicinal value of Indian gooseberry: A review | |
| Prabhakar et al. | Utility of indian fruits in cancer prevention and treatment: Time to undertake translational and bedside studies | |
| NZ796403B2 (en) | Therapeutic herbal compositions for improving joint health | |
| NZ796403A (en) | Therapeutic herbal compositions for improving joint health |